SUBSCRIBE: Print / eNewsletter
The breast cancer treatment landscape is changing, and the optimal adjuvant endocrine therapy for premenopausal women with hormone receptor (HR)-positive breast cancer is uncertain.
In his address, Dr. Clifford Hudis proposed the following solutions for achieving social justice in cancer care: creating more private and public resources, addressing disparities in cancer risk and in access to high-quality care, defining “value” in cancer care, and harnessing the new power of information technology.
While a prominent role for HE4 in these areas remains to be determined, this thorough review of HE4 demonstrates that the biomarker is complementary to, and occasionally more useful than, the widely used CA 125 in the management of gynecologic malignancies.
We've noticed that you're using an ad blocker
Our content is brought to you free of charge because of the support of our advertisers. To continue enjoying our content, please turn off your ad blocker.
